|
|
| (5 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Cilostazol#Contraindications]] |
| {{Cilostazol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Contraindication==
| |
| | |
| {|
| |
| |<div style="background: WhiteSmoke; float: left; text-align: left; padding: 1em;">
| |
| '''''Cilostazol (PLETAL) and several of its metabolites are inhibitors of [[phosphodiesterase]] III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV [[congestive heart failure]]. PLETAL is contraindicated in patients with congestive heart failure of any severity.PLETAL is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. PLETAL inhibits platelet aggregation in a reversible manner. PLETAL is contraindicated in patients with known or suspected hypersensitivity to any of its components<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref>'''''
| |
| </div>
| |
| |}
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |